Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Early P 1 (1)

Trial Status

Not Yet Recruiting2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07236177Early Phase 1Recruiting

B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.

NCT07260734Not Yet Recruiting

AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)

NCT06877507Not Yet RecruitingPrimary

Rapid Diagnostic Technology for AUGIB Based on Analysis of VOCs in Exhaled Breath

Showing all 3 trials

Research Network

Activity Timeline